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Summary Verapamil has been proposed to modulate the multidrug resistance phenotype by competitive
inhibition of an energy dependent efflux of cytotoxic drug. However, the accumulation of both '4C-verapamil
and 3H-verapamil was similar in wild type EHR2 and multidrug resistant EHR2/DNR+ Ehrlich ascites cells,
and was much less in both cell lines in energy deprived medium than in medium containing glucose. Azidopine
accumulation was also similar in both EHR2 and EHR2/DNR+ cells but, in contrast to verapamil, did not
differ significantly with changes in cellular energy levels. Azidopine photolabelled a 170 kDa protein in
EHR2/DHR+ plasma membrane vesicles which was immunoprecipitated by monoclonal antibody towards
P-glycoprotein. Azidopine increased daunorubicin accumulation and modulated vincristine resistance in
EHR2/DNR+ cells in a similar fashion to verapamil. Azidopine photolabelling was inhibited by vincristine
and verapamil, but not by daunorubicin. Vincristine, but not daunorubicin, was able to increase both
azidopine and verapamil accumulation in EHR2/DNR+ cells only. Finally, though both verapamil and
azidopine are a substrate for P-glycoprotein in EHR2/DNR+ cells, they do not themselves appear to be
transported by the multidrug resistance efflux mechanism to any significant extent in these cells.
The multidrug resistance (MDR) phenotype is characterised
by: (1) cross-resistance between structurally and functionally
unrelated drugs such as anthracyclines and vinca alkaloids;
(2) decreased intracellular drug levels in resistant cells com-
pared with wild type cells; (3) overexpression of a 170 kDa
plasma membrane glycoprotein called P-glycoprotein; and (4)
the ability of a number of amphipathic drugs to modulate
resistance (recently reviewed by Bradley et al., 1988). These
modulators are considered to act by increasing cytotoxic
drug levels in resistant cells by inhibiting their energy depen-
dent efflux. It was therefore of interest to examine whether
modulators had similar energy dependent accumulation pat-
terns as the cytotoxic drugs in wild type and resistant cells, a
finding which would be consistent with competitive inhibition
for drug efflux. Verapamil, the most studied modulator which
was first described by Tsuruo et al. (1981) and azidopine, a
dihydropyridine analogue which has the advantage of being
able to photoaffinity label P-glycoprotein (Safa et al., 1987)
were chosen for study.
Materials and methods
Cell lines
Wild type EHR2 and daunorubicin resistant EHR2/DNR +
cells have previously been described in detail (Dan0, 1971,
1973; Skovsgaard, 1978). EHR2/DNR + cells have all the
characteristics associated with the multidrug resistance
phenotype including cross resistance to vinca alkaloids and
decreased drug accumulation (Skovsgaard, 1978), modulation
by verapamil (Friche et al., 1987), and increased expression
of P-glycoprotein (Sehested et al., 1989a).
Chemicals
3H-verapamil (81.1 Ci mmol ') was purchased from New
England Nuclear (USA) while CN-'4-C-verapamil (12.9 mCi
mmol- ') was a generous gift from Knoll (FRG). 3H-azi-
dopine (45.2 Cimmol-') and unlabelled azidopine were from
Amersham (UK). Nonidet P40 was from Shell (UK). ATP
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and vincristine were obtained from Sigma (USA) and dauno-
rubicin from Farmitalia Carlo Erba (Italy). All other
chemicals were of analytical grade.
Measurement ofdrug accumulation in whole cells
Standard incubation medium was phosphate buffer pH 7.45
with 5% v/v dialysed calf serum and 10 mM glucose as
previously described (Skovsgaard, 1977). Experiments with
azidopine were performed in the dark. When depletion of
cellular energy was required, glucose was omitted and 10 mM
sodium azide added to the medium. After incubation with
either 3H-azidopine, 3H-verapamil or '4C-verapamil cells were
washed twice in ice-cold Ringer's solution by centrifugation,
and the final pellet solubilised with 1 ml of 0.1% v/v Nonidet
P40 overnight (solubilisation with either KOH or HCI
yielded similar results). Control experiments with pelleting
through silicone oil as described by Yusa et al. (1989) were
also performed. Daunorubicin accumulation was measured
by spectrofluorometry as previously described (Skovsgaard,
1977).
Clonogenic assay
This was performed as previously described (Roed et al.,
1987). Only continuous incubation with drug for 3 weeks was
used.
Photoaffinity labelling with azidopine
Plasma membrane vesicles from EHR2 and EHR2/DNR +
were photolabelled with 3H-azidopine as described by Safa et
al. (1987). Photolabelled proteins were analysed by SDS-
PAGE (9% gel), fluorography and photodensitometry.
Immunoprecipitation of P-glycoprotein was performed as
described by Mukhopadhyay and Kuo (1989) using the C219
monoclonal antibody against P-glycoprotein purchased from
Centocor (Belgium).
Results
Accumulation ofverapamil, azidopine anddaunorubicin in
whole cells
Figure 1 shows that the accumulation of '4C-verapamil in
EHR2 and EHR2/DNR + is similar over the course of 2 h.
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Figure 2 Accumulation of '4C-verapamil in EHR2/DNR + with
30 min incubation in medium containing 10 mM NaN3 without
glucose and then adding 10 mM glucose (0). Verapamil concen-
tration was 5l4M. Temperature was 37C. Accumulation in EHR2
followed the same pattern.
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Figure 1 Accumulation of '4C-verapamil in wild type EHR2
(a) and MDR EHR2/DNR + (b). Verapamil concentration was
5LM. Temperature 37C. Bars equal s.e.m. of triple determina-
tions. A, medium + 10 mM glucose; *, medium + 10 mM glu-
cose + 10 mM NaN3; *, medium + 10 mM NaN3.
Furthermore, reducing the cellular energy generation by
omission of glucose and addition of sodium azide demon-
strates that deprivation of energy leads to very low levels of
'4C-verapamil accumulation in both cell lines. This is further
illustrated in Figure 2, where the addition of 10 mM glucose
after 30 min of deprivation leads to a rapid increase in
'4C-verapamil accumulation. Accumulation of 3H-verapamil
(5pM) at 60 min, 37°C was also equal in both cell lines and
was likewise reduced by deprivation of cellular energy as
accumulation of the '4C-isotope (not shown). The effect of
daunorubicin, vincristine and azidopine on verapamil accum-
ulation is shown in Figure 3. Daunorubicin inhibited vera-
pamil accumulation in EHR2/DNR + by 15% at a 10-fold
molar excess. The greater inhibition in EHR2 cells is
presumably due to increased daunorubicin toxicity in the
wild type cells. The decrease in verapamil accumulation in
both EHR2 and EHR2/DNR + cells during simultaneous
azidopine incubation can also be ascribed to azidopine tox-
icity at the 25,.M level. However, vincristine in 10-25-fold
molar excess induced a small but statistically significant in-
crease in verapamil accumulation in EHR2/DNR + cells
only. Alteration of the cation composition in the incubation
medium by exchanging Na+ for K+ up to 80 mM K+ or by
addition of Ca2+ from 0 to 32 mM had no effect on vera-
pamil accumulation (not shown). Neither did the use of a
Tris instead of a phosphate buffer or when incubation media
and pelleting and extraction procedures according to Broxter-
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Figure 3 Effect of azidopine, daunorubicin and vincristine
on verapamil accumulation at 60min, 37C in EHR2 (a) and
EHR2/DNR + (b). The histogram is composed of independent
experiments with verapamil accumulation in standard medium
containing 10 mM glucose as 100%. Bars equal s.e.m. of triple
determinations. G, medium + 10 mM glucose with either 1, 2.5
or 5LM '4C-verapamil or 3H-verapamil. Alo, medium + 10 mM
glucose + 10-fold molar excess of azidopine (25 JiM). DIO,
medium + 10 mM glucose + 10-fold molar excess of daunorubicin
(50 J1M). V,0, medium + 10 mM glucose + 10-fold molar excess of
vincristine (lIO1M). V25, medium + 10mM glucose + 25-fold
molar excess of vincristine (25piM). 0, P< 0.02 (Student's t test)
versus G.
man et al. (1988), Kessel and Wilberding (1984) or Yusa et
al. (1989) were used (not shown). Accumulation of verapamil
was sensitive to variation in medium pH being approximately
50% higher at pH 7.45 than at pH 7.20 (not shown).
Furthermore, verapamil accumulation was temperature
dependent being approximately 50% lower at 4°C compared
with 37C (not shown), which is in agreement with findings
by Kessel (1986).
On the other hand, the accumulation pattern of azidopine
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was entirely different from that of verapamil as demonstrated
in Figure 4 in that accumulation is rapid and with only
minor effect of manipulation of cellular energy levels. The
decrease in azidopine levels over time in medium containing
sodium azide in both cell lines suggest that this is due to an
additive toxic effect. However, as for verapamil, steady state
azidopine levels are similar in both cell lines. Azidopine
increased daunorubicin accumulation in EHR2/DNR + cells
in a dose dependent manner (Figure 5). Finally, though a
10-fold molar excess of daunorubicin had no effect on azi-
dopine accumulation, there was a slight but statistically
significant dose dependent effect of verapamil in 5-25-fold
molar excess on azidopine accumulation in EHR2/DNR +
cells but not in EHR2 cells (Figure 6). Vincristine in 10-fold
molar excess also significantly increased azidopine accumula-
tion in EHR2/DNR + cells (Figure 6).
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Figure 4 Accumulation of 3H-azidopine in EHR2 (a) and
EHR2/DNR + (b) at 37°C. Azidopine concentration was 2lLM.
0, medium + 10 mM glucose; 0, medium + 10 mM NaN3.
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Figure 6 Influence ofvincristine, verapamil and daunorubicin on
3H-azidopine accumulation in EHR2 (a) and EHR2/DNR + cells
(b) measured at 60 min, 37°C. Azidopine concentration was 1 lAM.
Bars equal s.e.m. of triple determinations. A, medium + 10 mM
NaN3. G, medium + 10 mM glucose. D,o, medium + 10 mM glu-
cose + 10liM daunorubicin. V,0, medium + 10 mM glucose +
10tsM vincristine. VP5, medium + 10mM glucose + 5fiM vera-
pamil. VP,0, medium + 10 mM glucose + 10 lM verapamil. VP25,
medium + 10mM glucose + 25 ,LM verapamil. 0, P<0.05 (Stu-
dent's t test) versus G. 0, P<0.0l versus G. @ , P<0.05
versus VP5. *@@@, P<0.001 versus VP,0.
Mr X 10-3
150-
NaN3
66-
1 5 10 15
F.M Azidopine
Figure 5 Dose-response curve of the effect of increasing con-
centration of azidopine on daunorubicin accumulation in EHR2/
DNR + cells in medium containing 10 mM glucose measured at
60min, 37C. Daunorubicin concentration in medium was 5 lAM.
NaN3 line was daunorubicin accumulation in medium without
glucose + 10 mM NaN3.
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Figure 7 Photoaffinity labelling of plasma membrane vesicles
with azidopine. Membrane vesicles from EHR2 and EHR2/
DNR + were labelled with 3H-azidopine at 0.41 liM. Fluoro-
graphs were obtained after SDS-PAGE (50 lg protein per lane).
Lane 1, EHR2. Lanes 2-6 EHR2/DNR +: lane 3, + 83IM
unlabelled azidopine; lane 4, + 42lM verapamil; lane 5,
+42 liM vincristine; lane 6, +42lM daunorubicin. Lane 7,
immunoprecipitation of 3H-azidopine labelled P-glycoprotein.
Photoaffinity labelling and immunoprecipitation of
P-glycoprotein
3H-azidopine photolabelled a 170 kDa protein in plasma
membrane vesicles from EHR2/DNR + only (Figure 7, lanes
1 and 2), and immunoprecipitation with monoclonal anti-
body C219 confirmed azidopine labelling of P-glycoprotein
(Figure 7, lane 7). In repeated experiments, vincristine
inhibited labelling of P-glycoprotein as measured by den-
sitometry scans by 41-80% at 100-fold molar excess (e.g.
Figure 7, lane 5). Verapamil inhibited azidopine labelling by
38-73% at 100-fold molar excess (e.g. Figure 7, lane 4),
while daunorubicin did not inhibit azidopine labelling in any
of three experiments at 100-fold molar excess (e.g. Figure 7,
lane 6).
Clonogenic assay
Both verapamil and azidopine act as typical multidrug resis-
tance modifiers in EHR2/DNR + cells (Figure 8), azidopine
being more efficient as modulator than verapamil but also
more toxic by itself. Separate experiments showed that
verapamil was more toxic to EHR2 cells with an IC50 of
55 lM than to EHR2/DNR + with an IC50 of 90;LM (not
shown).
I
r., tt a
0 0 .040 M. SEHESTED et al.
0.11
0.00 0.05 0.10 0.15 0.20 0.25 0.30
Vincristine FLM cont
Figure 8 Clonogenic assay demonstrating modulating ability of
1.0tiM ( ) and 2.5giM ( - ) azidopine compared with
2.5 ,iM (....) and 5 ItM (+ + verapamil on vincristine resis-
tance in EHR2/DNR + cells. (- ---) is vincristine alone. Bars
equal s.e.m. of triple determinations.
Discussion
The MDR1 gene mRNA is overexpressed in a number of
human tumours (Fojo et al., 1987) and the modulation of the
MDR phenotype could therefore well have clinical impor-
tance. The overexpression of P-glycoprotein appears to be
essential to the MDR phenotype of increased drug efflux
(Bradley et al., 1988) and the relationship between modulator
and P-glycoprotein has therefore received a great deal of
attention. Verapamil is the best documented modulator since
its description by Tsuruo et al. (1981), and has also been
shown to inhibit daunorubicin efflux and modulate resistance
in our EHR2/DNR + cell line (Friche et al., 1987 and
Figure 8). Verapamil has been reported to have an accumula-
tion pattern typical of drugs in the MDR family, i.e.
decreased accumulation in MDR cells compared to wild type
cells in medium containing glucose (Broxterman et al., 1988;
Cano-Gauchi & Riordan, 1987; Kessel & Wilberding, 1984;
Warr et al., 1988; Yusa and Tsuruo, 1989) and increased
accumulation in resistant cells after deprivation of cellular
energy sources (Kessel & Wilberding, 1984). However, as
demonstrated in Figures 1 and 2, the accumulation pattern of
verapamil is similar in both EHR2 and EHR2/DNR + cells
and furthermore shows the opposite reaction to deprivation
of cellular energy to that of MDR drugs like daunorubicin
and vincristine in the same cell lines (Skovsgaard, 1978). This
difference in the verapamil accumulation pattern in EHR2
and EHR2/DNR + cells compared with other described
MDR cell lines is hardly due to experimental procedures as
we have tried a variety, including copies of those of Broxter-
man et al. (1988), Kessel and Wilberding (1984) and Yusa
and Tsuruo (1989) and have furthermore also used two
different verapamil isotopes. It is also unlikely that the lack
of a demonstrable verapamil efflux 'pump' in EHR2/DNR +
is due to its being overshadowed by a more rapid influx as
influx is slower than for daunorubicin (Figure 1 and Skovs-
gaard, 1978). Interestingly, several MDR cell lines have been
reported to be hypersensitive to verapamil itself (Cano-
Gauchi & Riordan, 1987; Twentyman et al., 1986; Warr et
al., 1988). This is not the case for EHR2/DNR + which has
a higher IC50 value of 90ZM verapamil compared to 55 tAM
for EHR2 in a 3-week continuous incubation clonogenic
assay, a cross resistance which is clearly not caused by
reduced accumulation (Figure 1). Recently other murine
MDR cell lines which are also cross resistant to verapamil
have been described (Reeve et al., 1989).
The dihydropyridine analogue azidopine has received great
interest in characterisation of the MDR phenotype since its
original description by Safa et al. (1987) as it is inherently
photoreactive (Bruggemann et al., 1989; Kamiwatari et al.,
1989; Schurr et al., 1989; Yang et al., 1988; Yoshimura et al.,
1989). However, to our knowledge, the modulating properties
of azidopine as well as its own cellular accumulation have
not been previously described. As shown in Figures 5 and 8,
azidopine is a typical modulator with an efficiency exceeding
that of verapamil in EHR2/DNR + cells (Figure 5 and
Friche et al., 1987), though it is considerably more cytotoxic
by itself than verapamil (Figure 8). It typically photolabels
P-glycoprotein in plasma membrane vesicles from EHR2/
DNR+ cells (Figure 7) as previously described in other
MDR cell lines (Safa et al., 1987). Thus, though azidopine
binds to P-glycoprotein, there is no difference in its
accumulation between wild type and resistant cells (Figure 4).
In fact, the accumulation of azidopine is remarkably similar
to that reported for nitrendipine (Kessel, 1986). Similar
results have been described for the modulating bisbenzyliso-
quinoline alkaloid cepharanthine, which is also accumulated
in equal amounts in wild type and resistant cells (Shiraishi et
al., 1987) and which also inhibits azidopine labelling of P-
glycoprotein (Asoh et al., 1989; Kamiwatari et al., 1989).
Yusa and Tsuruo (1989) reported that a 1,740-fold excess
of vinblastine was able to increase 3H-verapamil accumula-
tion by 40% in MDR K562/ADM cells thus reaching to a
level of 43% of that of wild type K562 cells. We also found
that vincristine significantly increased verapamil accumula-
tion in EHR2/DNR + cells (Figure 3) and furthermore that
vincristine and verapamil also increased azidopine accumula-
tion (Figure 6) to levels which exceeded those found in wild
type EHR2 cells. This curious phenomenon of drug levels in
MDR cells exceeding those in wild type cells has not, to our
knowledge, previously been described. It is not readily
explained, but could be due to altered intracellular distribu-
tion of these modulating drugs caused by activation of P-
glycoprotein.
Recently, two azidopine binding sites on P-glycoprotein
have been detected (Bruggemann et al., 1989), with the C
terminal one being mostly labelled (Yoshimura et al., 1989).
Azidopine photolabelling of P-glycoprotein in EHR2/
DNR + is inhibited by a large (100-fold) molar excess of
both vincristine and verapamil to roughly the same extent as
described by Safa et al. (1987), but not by daunorubicin
(Figure 7). Safa also found only a slight (19%) inhibition of
azidopine labelling by a 200-fold molar excess of another
anthracycline, namely doxorubicin. This inhibition pattern of
azidopine photolabelling is in agreement with results in
Figure 6 where both vincristine and verapamil significantly
increase azidopine accumulation in EHR2/DNR + but not
EHR2 cells while daunorubicin has no effect. Furthermore,
although verapamil at a 5-fold molar excess increases
daunorubicin accumulation in EHR2/DNR + at least 400%
(Friche et al., 1987), daunorubicin does not increase vera-
pamil accumulation even at 10-fold molar excess (Figure 3),
a result which is in agreement with Kessel (1986). Vincristine
however, whose accumulation in EHR2/DNR + cells is in-
creased at least 500% by a 10-fold molar excess of verapamil
(Sehested et al., 1989b) is only able to increase verapamil
accumulation by 37% at a similar molar excess (Figure 3).
Thus, daunorubicin appears to interact differently with P-
glycoprotein in EHR2/DNR + cells compared to azidopine,
verapamil and vincristine.
In conclusion, though azidopine and verapamil are sub-
strates for P-glycoprotein in EHR2/DNR + cells and could
thereby modify P-glycoprotein function, they do not them-
selves follow the MDR efflux pathway to any detectable
degree in these cells.
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